期刊
CELL DEATH & DISEASE
卷 12, 期 8, 页码 -出版社
SPRINGERNATURE
DOI: 10.1038/s41419-021-04012-z
关键词
-
类别
资金
- major national S&T projects for infectious diseases [2018ZX10301401]
- Key Research & Development Plan of Zhejiang Province [2019C04005]
- National Key Research and Development Program of China [2018YFC2000500]
The study found significant differences in m6A profiles between severe and mild COVID-19 patients, with RBM15 being a major m6A methyltransferase positively correlated with disease severity. By elevating m6A modifications of multitarget genes, RBM15 regulates host immune response to SARS-CoV-2, indicating its potential as a target for COVID-19 treatment.
Severe coronavirus disease 2019 (COVID-19) is characterized by symptoms of lymphopenia and multiorgan damage, but the underlying mechanisms remain unclear. To explore the function of N6-methyladenosine (m6A) modifications in COVID-19, we performed microarray analyses to comprehensively characterize the m6A epitranscriptome. The results revealed distinct global m6A profiles in severe and mild COVID-19 patients. Programmed cell death and inflammatory response were the major biological processes modulated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Further, RBM15, a major m6A methyltransferase, was significantly elevated and positively correlated with disease severity. Silencing RBM15 drastically reduced lymphocyte death in vitro. Knockdown of RBM15 remarkably suppressed the expression levels of multitarget genes related to programmed cell death and inflammatory response. This study shows that SARS-CoV-2 infection alters the m6A epitranscriptome of lymphocytes, particularly in the case of severe patients. RBM15 regulated host immune response to SARS-CoV-2 by elevating m6A modifications of multitarget genes. These findings indicate that RBM15 can serve as a target for the treatment of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据